Clark Laboratories, Inc. (dba,Trinity Biotech USA)
FDA classification date
Dec 16, 2014
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III
Reason stated in the source
Through in-house routine real time stability monitoring of Trinity's Captia Syphilis IgM Capture Test Kit, Lot 033, the firm identified a failure of the kit to meet its labeled expiry dating of 6 months.
Source facts
Action
Recall notification letters were sent by e-mail to 2 US customers on 11/17/2014 and 11/19/2014. The remaining US customers were sent the letter by FedEx on 11/19/2014. Customers are instructed to discontinue use of any remaining inventory (discard on site if any remain) and provide date of last use (run) and if they obtained valid or invalid runs. Additionally, Trinity is in the process of sending the recall letters to the required EU Regulatory Authorities and the 3 foreign distributors.
Initiated
2014-11-17
Root cause
Under Investigation by firm
Terminated
2016-05-24
Distribution
New York, Florida, Utah, and California plus foreign distribution to Spain and France
Recall number
Z-0819-2015
Recall status
Terminated
CDRH record ID
131724
FDA classified
2014-12-16
Recall event number
69827
Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.
Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.